Good afternoon, and welcome to the Senseonics Third Quarter 2017 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions]. After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions]. Please note, this event is being recorded. I now would like to turn the conference over to Don Elsey, Chief Financial Officer. Please go ahead.

Thank you very much, and welcome to the third quarter 2017 Senseonics earnings call. Before we begin today, let me remind you that the company’s remarks include forward-looking statements. These statements reflect management’s expectations about future events, operating plans, regulatory matters, product enhancements, and company performance, and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties. A list of the factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is detailed under Risk Factors and elsewhere in our Annual Report on Form 10-K and our other reports filed with the SEC. These documents are available in the Investor Relations section of our website at www.senseonics.com. We undertake no obligation to update publicly or revise these forward-looking statements for any reason except as required by law. With that, I will now turn the call over to Tim Goodnow. Tim?

Thank you, Don. Entering the final quarter of 2017, we are pleased with our accomplishments this year and are looking forward to an exciting and transformational year in 2018. In the third quarter, we had a significant new product approval, meaningful new market launches, a new milestone in quarterly revenue and balancing improvement with the successful capital raise. Our current commercial focus is on Europe, where we are preparing to launch Eversense XL, while expanding our presence to both deeper and broader market penetration. In the U.S., we are preparing for a launch into the rapidly changing diabetes market environment. It’s very clear that the pace of innovation for diabetes management is increasing. It’s also evident that users and clinicians are clearly seeing its acceleration and appreciate the value of new technologies. CGM has become the standard of care for people using insulin to manage their diabetes. Expanded CGM capabilities, including new generation prospective CGMs, as well as flash glucose monitoring will expand utilization, expand the market and help improve diabetes management for more people. Now more than ever, we feel favorably positioned and uniquely differentiated as the only long-term continuous glucose monitoring system within this environment. On the call today, I will address the current state of our business, Don will provide more details on our financials, and then I’ll wrap up with some comments about our strategic direction at Senseonics and our focus on the advantages of the long-term wear Eversense System. First, we generated just over $2 million in revenue from Europe in the third quarter. This was more than the past quarters combined and in line with our expectation as we are beginning to scale. We expect a continued increase in sales throughout the fourth quarter, as we have transitioned to full launch in many of…

Thank you, Tim. For the three months ended September 30, 2017, we generated $2.1 million in revenue compared to $37,000 in the prior-year period. The increase was attributable to sales of the Eversense sensor in Europe. For the three months ended September 30, 2017, total net loss was $17.4 million, or $0.13 per share, compared to $10.9 million, or $0.12 per share in the third quarter of 2016. Third Quarter 2017 net loss per share is based on $128.9 million weighted average shares outstanding, compared to $93.4 million weighted average shares outstanding in the third quarter of 2016. For the nine months ended September 30, total net loss was $42.8 million, or $0.39 per share, compared to $34 million loss, or $0.39 per share in the first nine months of 2016. The first nine months of 2017 net loss per share is based on $109 million weighted average shares outstanding, compared $87.8 million weighted average shares outstanding in the first time months of 2016. The largest driver of the increase in net loss for both the three and nine-month periods was generally higher operating expense, as we grew the organization to support the broaden launch in Europe and began to prepare for the U.S. launch. I’d like to now turn to our balance sheet at quarter-end. At the end of the third quarter, our cash, cash equivalents and marketable securities were $52.7 million. This is inclusive of the equity raise of just over $26 million that we completed in August. Let me turn to guidance for the year. As Tim mentioned earlier, we are reiterating our expectations for full-year revenue between $6 million and $7 million with additional confidence driven by our expanding launch presence. I will now turn the call back over to Tim.

Thank you, Don. As we push forward our product development initiatives, we are also continuing to work on an integrated automated insulin delivery system combining Eversense with the TypeZero artificial pancreas algorithm and the Roche Accu-Chek Insight pump. The integrated AID system is in full development, whereby the TypeZero inControl algorithm is being incorporated into our Eversense path, which then controls the Insight pump. The three organizations are focused on delivering a mobile-based long-term closed-loop system to support the needs of people with diabetes. As you may be aware, this is part of the NIH-sponsored International Diabetes Closed Loop trial, and our efforts will be utilized in the European study arm to be conducted at the Academic Medical Center in Amsterdam; the University CHR hospital in Montpellier, France; the University of Padova in Italy; all being coordinated by the JAEB Center For Health Research in Florida. We are also happy to announce the completion of the first clinical trial of the Eversense 180-day sensor with pediatric participants in Canada. Feedback has been very positive with much commentary on the simplicity and seamless integration into their lives. One patient in the study was a 12-year-old boy, who played several school sports; hockey, cross-country, soccer, volleyball and basketball. His parents described Eversense as amazing, very accurate and reliable. With the Eversense System, their son literally forgot it was there. He caught his highs and lows and treated them accordingly. The device worked when it mattered most on the eyes and when he was sleeping. Another patient was a young adult who described her numbers as previously always being out of whack. This was due to her sports and her very active lifestyle. Late night glycemic episodes were all too frequent due to her busy physical life. Her mother described Eversense as a…

We will now begin the question-and-answer session [Operator Instructions] Our first question comes from Danielle Antalffy with Leerink Partners. Please go ahead.

Hey, good afternoon, guys, and congrats on a really great quarter. Great to see the adoption momentum building there. Tim, I was hoping you could comment, we obviously had a big competitive product approval here in the United States and pricing is coming into question for the CGM market broadly. I was wondering if you could provide us with your views on how you’re thinking about the pricing dynamic now with potentially – wow with a much cheaper product on the market?

Sure, Danielle, and it’s good to see you always up first with questions, we appreciate that. Obviously, bringing the Libre into the market, quite frankly, it’s going to be a very positive for many people with diabetes. I think, what we’re seeing obviously is the broad acceptance in Europe, especially with patients that have previously, of course, had been doing fingersticks. It certainly is a different product and really designed to add incremental value to folks that are testing discretely with the fingerstick devices. But as you’re obviously aware, it does not have the different functionality, there’s prospective capability that pull CGMs out. So we do anticipate that there will continue to be some pricing differential between the two technologies, the two offering solutions. With that said, I think, we have always taken the position that pricing is only going to go one direction in healthcare. There’s always going to be pricing pressure to reduce the cost to society, and we’ve been anticipating that and planning on it from the very beginning day. The key value from a business perspective that we have always seen in these long-term sensors is the ability to utilize that lengths to the point where we can support any new pricing pressure that may occur and will occur in the market. So I don’t know where it’s going to be, Danielle. I don’t know specifically what we will drive in it. It certainly will offer some alternatives for some folks. But we’re seeing a lot of folks that are quite interested in actually making that transition once they used to wearing a sensor up to a continuous sensor has been, it’s been more attractive than we initially thought it would be. So we’re pretty excited about that part of it.

Got it. Thank you.

Hope that helps.

Yes. No, that’s very helpful. And actually just a follow-up on that point. So I think, you said in the prepared remarks, 75% of your patients are switchers than only a quarter are new to CGM therapy. So just wondering, I have always viewed this as potentially driving switchers, but really broadening the market. Now that you’re investing in direct-to-consumer type marketing initiatives, you expect that quarter number to grow and you expect to see going forward just as many new patient adds to CGM therapy versus switching from other devices, or help us think about how we should think about the mix between new patients and switchers?

Yes, I mean, we do expect that it is going to grow. Right now, you’re in that phenomenon of a new product launch, where your earliest adopters are most attentive. And that, obviously, is the folks that already have some CGM experience. So it’s not to be unexpected that they might be over indexed in the beginning. Obviously, we’re interested in bringing the product to the people they can use it most and have the most interest in it. There are a number of folks that made the decision not to go to on CGM for one reason or another that we think are good candidates for a long-term sensor. So I do think it will change over time. But at this point, I think, having the focus on early adopters, the reality of early adopters is probably what drives some of that index.

All right. Thanks so much.

The next question comes from Kyle Rose of Canaccord Genuity. Please go ahead.

Great. Thank you very much for taking the questions. Can you guys hear me all right?

Sure, Kyle. How are you?

I’m well. Congrats on a strong quarter. So I wanted to touch a little bit on the – just the plans for the transition from the Eversense to the Eversense XL, particularly in the international markets. And then I guess, because you talked about the trial in the U.S. probably you could touch on that. But again, how do you think of the pricing dynamics to change when you launch the XL into your distributors and how should we be thinking about modeling an AFP lift over time?

I’m going to ask Mirasol, who’s dealing with this on a daily basis with our distribution partners to give her perspective on.

Yes, and we’re still working through what the final pricing is going to be for XL. But the feedback that we’ve gotten Kyle is that, this is definitely a very non-traditional exciting new product addition to the marketplace and highly differentiated even compared to our own Eversense 90-day sensor. And so when you add all of the benefits of the long-term, we’re up 280 with the adhesive and the vibe alerts really adds up and it’s really differentiated from the others, again, the last seven to 14 days. So I think, once we will layout, we’ll provide you with a little bit more understanding of how our pricing is.

Okay. Right now I appreciate that. And when – you gave some additional updates as far as the U.S. market, and I just want to make sure that I’m interpreting your comments correctly, Tim. But it sounds like panels obviously going to slip into the early part of 2018, all goes approval shortly thereafter maybe like that end of Q1, start of Q2, but you get approval. And then you’ve got two months where you need to fine tune some of the things as far as the commercial plan goes before you can enter the U.S. markets. So I guess, is the way to think about this from an U.S. market entry really more of a second-half event some maybe some are 80 around 80 A next year?

Yes, obviously, Kyle, we’re highly motivated to do everything that we can to do as quickly as possible, of course. But to help give some guidance on the feeling on timing, this clearly is going to be a second-half ramp just like we’re seeing in Europe. But your timing, I wouldn’t necessarily strongly argue with, we’d like to do it a little bit earlier than that. But I do think the reality is, once we do the final conversations with the FDA, that typically is around the agreement is okay. This is exactly what your labeling we’ll say. And then we need to go into production and assembly of all of that. So as you’re seeing with those in the space that takes about two months to do that process. So, to help you guys think a little bit about the timing the way we do, we wanted to try to put that out there.

I appreciate that. And then one last question and I’ll get back in queue. When we think about, obviously, you’ve got very strong momentum in patient demand internationally, particularly when we think about the Q3, it sounds like that momentum only continues to grow into the Q4. How should we think about the quarterly progression through 2018? Is there any reason to think that given the early stage of the commercialization that you can’t continue to grow on a discrete new patient basis quarter-over-quarter for the next several quarters?

We’re certainly going to try to do that, Kyle, but I don’t want to jump ahead for guidance for 2018 yet. We’re certainly going to do that on the next call. We’ve got some more work to do. As you know, with the distribution partners, it’s just one more level of complexity. So if I can hold to the next time that we formally speak on guidance that would help, but our – obviously, our intention is to continue to grow and accelerate the launch.

Terrific. Thank you very much for taking the questions.

[Operator Instructions] The next question comes from Jayson Bedford with Raymond James. Please go ahead.

Hi. Can you hear me, okay?

We can, Jayson. How are you?

Doing well, thanks. So just a few questions. First, on the top line, I realized it’s a relatively small numbers here. But you showed a pretty nice sequential jump in sales. Is there anyway you can give us a little flavor as to where meaning kind of in which geographies you saw the growth sequential?

The biggest chunk was from their earliest biggest markets as – it’s pretty well understood that Germany is a second largest market in the world. We were there early. Sweden is a great market as well, and Italy is a very good market. So those are the three biggest drivers and most important markets for us right now until we get to the United States.

And Tim, in Germany, can you comment just on reimbursement and how broad it is in that country right now?

I’ll let Mirasol touch on that. It’s quite attractive as you know. But I’ll let Mirasol give some specifics.

And similarly with the CGM being reimbursed in Germany, that bodes very well for us. We have a number of prescriptions already. And so it’s a little bit different for us, however, because we have a different reimbursement code than the other CGMs. But the prescriptions are just coming in and so we’re very pleased with how that’s going.

Okay. In terms of the 13 countries, how many are in full launch mode right now?

That’s a good question. We have four that is in full launch mode. And of course, the six that we just started with are – probably it will take sometime before we move them over to the full launch mode.

Okay. And then just on the regulatory side, the FDA certainly seems more flexible today than they’ve been in the past. I’m wondering if that has kind of opened the door a little bit for you either with the opportunity to introduce the transmitter into your U.S. submission, or any new thoughts around your ability to gain the dosing claim?

Yes, those are great questions and common conversation. Obviously, our objective is to achieve both of those in this submission. At the same time, we’re in that precarious situation of obviously doing everything we can to push the primary approval, and we wouldn’t want to put that at any material risk. That said, this is a very open group, and they’re very approachable. I think we’ve met with them only for what four or five times…

Five times, yes.

…in this approval process. So they’re very open to have the conversations. It’s always a matter of timing. And we love to have it to determine what the impact to the total duration might be to bring in the smaller transmitter for that ever-interesting dosing claim. I do think the world has changed potentially a little bit around dosing. We need to spend some more time with them to fully understand that as what it might mean for us.

Okay. Thank you.

All right. Thank you

This concludes our question-and-answer session. I would like to turn the conference back over to Tim Goodnow for any closing remarks.

Great. Once again, we want to thank everyone for their time during this busy season and support, and we appreciate everyone’s focus in questions as well. We look forward to talking with you at the next quarterly call. With that, we’ll conclude. Have a great evening.

The conference is now concluded. Thank you for attending today’s presentation. You may now disconnect.